Selexis offers comprehensive and rapid solutions for stable, high yield mammalian cell lines used in recombinant protein manufacturing of therapeutic drugs. The Company's unique SURE Cell Line Development services and technology, which includes Selexis’ patented Selexis Genetic Elements™, reduces traditional cell line development (e.g. DHFR) from 12 months to ~5 weeks*. Additionally, Selexis Genetic Elements™ improves the yield and stability of production cell lines and has been found to increase recombinant protein expression in mammalian cells in suspension and in serum-free more than 20 fold.
